<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108884</url>
  </required_header>
  <id_info>
    <org_study_id>2019-00908</org_study_id>
    <nct_id>NCT04108884</nct_id>
  </id_info>
  <brief_title>RedStroke - Reducing Europe's Stroke Incidence</brief_title>
  <acronym>RedStroke</acronym>
  <official_title>RedStroke - Reducing Europe's Stroke Incidence: Highly Cost-effective Population Screening Programs for Atrial Fibrillation Coupled With High Diagnostic Yield Confirmation Services</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Preventicus GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the RedStroke study, the effect of a smartphone application in detecting Atrial
      Fibrillation (AF) will be assessed in a double-blind randomised controlled multicenter trial.
      Outpatients with an elevated risk for atrial fibrillation will be randomized to an
      intervention arm (app group) and to a standard-of-care arm (control group). Both groups will
      have the app installed on their private smartphones and will be asked to perform a predefined
      measurement protocol. All patients will continue their prior therapy with their general
      practitioner and obtain every medical treatment indicated. This study will not cause any
      restrictions on the usual treatment of the study patients.

      The only difference between the two groups will be, that patients in the app group will be
      informed by their local PI, if the recordings of the app indicate AF (and obtain a 14 day
      Holter ECG for AF verification), whereas the patients in the &quot;usual care&quot; group will obtain
      the read out of the app at the end of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In this study, the effect of a smartphone application in detecting AF will be assessed in a double-blind randomised controlled trial. Patients will be randomized to an intervention arm (app group) and to a standard-of-care arm (control group). Both groups will have the app installed on their private smartphones and will be asked to perform a predefined measurement protocol. The only difference between the two groups will be, that patients in the &quot;app&quot; group will be informed by their local PI, if the recordings of the app indicate AF, whereas the patients in the &quot;usual care&quot; group will obtain the read out of the app at the end of the study (6 months after inclusion).</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Patients and study team will remain blind to the assigned groups until the end of the trial. Only in case of a positive app finding, patients and site team will be unblinded for the remaining time of the trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Atrial Fibrillation</measure>
    <time_frame>6 months</time_frame>
    <description>Prevalence of Atrial Fibrillation confirmed by ECG in the app group compared with the standard care group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Costs related to the AF screening</measure>
    <time_frame>6 months</time_frame>
    <description>Health care resource utilization data related to AF diagnosis will be collected for all patients during the study. To evaluate the clinical consequences associated with screening, additional endpoints include the initiation of AF-related therapies including anticoagulants, antiarrhythmic agents or hospitalizations with a primary diagnosis of AF. As a general measure of health care utilization, hospitalization for any cause will also be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance of patients using the app</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients who regularly use the app according to study instructions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>App Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the app group, if an episode of arrhythmia is detected with the app, the local investigator will contact the respective patient to schedule an appointment for a 14 day Holter ECG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The control group will perform the same measurements as the intervention group, with the only difference that a cumulated Portable Document Format (PDF) report is provided after 6 months instead of the immediate feedback in the app group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>App measurement</intervention_name>
    <description>App measurement twice a day in the first two weeks after enrollment and twice a week (on different days) from the third week onward and whenever patients feel palpitations</description>
    <arm_group_label>App Group</arm_group_label>
    <arm_group_label>Standard Care Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>14 day Holter ECG</intervention_name>
    <description>14 day moblie patch Holter ECG for AF confirmation</description>
    <arm_group_label>App Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  CHA2DS2-VASc score of 3 and above, if patients are aged under 65 years

          -  CHA2DS2-VASc score of 2 and above, if patients are aged 65 years or older

        Exclusion Criteria:

          -  history of Atrial Fibrillation

          -  current anticoagulation treatment,

          -  cardiac implanted electronic device (ICD or/and PM)

          -  app cannot be installed due to technical problems (smartphone type, reduced smartphone
             storage capacity, other)

          -  inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia, etc. of the participant

          -  enrollment of the investigator, his/her family members, employees and other dependent
             persons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Eckstein, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Eckstein, MD, PhD</last_name>
    <phone>+41 61 32</phone>
    <phone_ext>87689</phone_ext>
    <email>jens.eckstein@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aura Winterhalder</last_name>
    <phone>+41 61 32</phone>
    <phone_ext>86677</phone_ext>
    <email>aura.winterhalder@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medicine Greifswald</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcus DÃ¶rr, MD, Prof.</last_name>
      <phone>+49 3834 86 80510</phone>
      <email>marcus.doerr@uni-greifswald.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepeion Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attica</state>
        <zip>17121</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>. Athanasios J. Manolis, MD, Prof.</last_name>
      <phone>+ 30 6944 946394</phone>
      <email>ajmanol@otenet.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Maastricht</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6200 MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrich Schotten, MD PhD Prof.</last_name>
      <phone>+31 43 3881077</phone>
      <email>Schotten@maastrichtuniversity.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University Medical College</name>
      <address>
        <city>Krakow</city>
        <state>Lesser Poland</state>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dariusz Dudek, MD PhD Prof.</last_name>
      <phone>+ 48 12 4247181</phone>
      <email>mcdudek@cyfronet.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Svetozar Putnik, MD Prof.</last_name>
      <phone>+381 63 7234560</phone>
      <email>svetozar073@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitiy Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thilo Burkard, MD</last_name>
      <phone>+41 61 32</phone>
      <phone_ext>87738</phone_ext>
      <email>thilo.burkard@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Aura Winterhalder</last_name>
      <phone>+41 61 32</phone>
      <phone_ext>86677</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paulus Kirchhof, MD PhD Prof.</last_name>
      <phone>+44 121 414 7042</phone>
      <email>p.kirchhof@bham.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Smartphone App</keyword>
  <keyword>CHA2DS2-VASc-Score</keyword>
  <keyword>Screening</keyword>
  <keyword>Cardiovascular risk factors</keyword>
  <keyword>Outpatient setting</keyword>
  <keyword>Congestive heart failure</keyword>
  <keyword>Stroke</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Vascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

